<DOC>
	<DOCNO>NCT00771472</DOCNO>
	<brief_summary>Part I evaluate safety , tolerability pharmacokinetics ( PK ) vorinostat Japanese patient relapse refractory CTCL . Part II evaluate safety vorinostat Japanese pt . relapsed refractory CTCL . Relapsed refractory CTCL patient newly enrol Part II .</brief_summary>
	<brief_title>Vorinostat ( MK-0683 ) Phase I Study Cutaneous T-Cell Lymphoma ( CTCL ) Patients ( MK-0683-089 EXT1 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Inclusion Criteria ( Parts I &amp; II ) : Patients With CTCL Who Have Progressive , Persistent Or Recurrent Disease Subsequent To At Least One Prior Therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status Must Be 02 Patients Have Adequate Bone Marrow , Liver Function And Renal Function Exclusion Criteria ( Parts I &amp; II ) : Patients Had Prior Therapy Within 3 Weeks Before Registration , Or Have Not Recovered From Toxicities Of Prior Therapy Patients Have Uncontrolled Intercurrent Illness Pregnant Or Women Have A Will To Be Pregnant And Lactating Woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>